EVT 301

Drug Profile

EVT 301

Latest Information Update: 15 Sep 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antidementias
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 15 Sep 2006 Discontinued - Phase-I for Alzheimer's disease in European Union (PO)
  • 09 Jan 2006 EVT 301 has been licensed to Evotec worldwide
  • 09 Jan 2006 Phase-I clinical trials in Alzheimer's disease in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top